Skip to main content
letter
. 2024 Oct 31;10(1):38–42. doi: 10.17996/anc.23-00014

Table 1. Demographic and clinical characteristics of patients with TGCV investigated.

Patients (N=9)
Age of diagnosis 58.6±11.1*
Sex: Male/Female (n) 6/3
Body mass index (kg/m2) 19.1±5.5*
Hemodialysis duration (days) 5,244±4,249*
Etiologies of end stage renal disease (n) ADPKD (1), Nephrosclerosis (2), Diabetic nephropathy (3), FSGS (1), Unknown (2)
Co-morbidities
 Diabetes mellitus (n) 4
 Dyslipidemia (n) 2
 Hypertension (n) 6
Hemoglobin (g/dL) 11.4±1.3*
Serum lipid levels (mg/dL)
 Triglyceride 111±47*
 Low-density lipoprotein-cholesterol 72±25*
 High-density lipoprotein-cholesterol 50±11 *
Low LVEF (<40%) (n) 2
Diffuse coronary atherosclerosis (n) 7
Outcomes
 Follow-up period from TGCV diagnosis (days) 1,713±1,996*
 All-cause of death (n) 4
*

Mean±standard deviation

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; LVEF, left ventricular ejection fraction; N, number; TGCV, triglyceride cardiomyovasculopathy